— Know what they know.
Not Investment Advice
Also trades as: EMBCV (NASDAQ) · $vol 116M

EMBC NASDAQ

Embecta Corp.
1W: +0.0% 1M: +10.6% 3M: -62.7% YTD: -70.1% 1Y: -69.1% 3Y: -80.7%
$3.60
+0.16 (+4.66%)
 
Weekly Expected Move ±9.4%
$3 $3 $3 $4 $4
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Buy · Power 58 · $203.8M mcap · 58M float · 4.38% daily turnover · Short 51% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$203.8M
52W Range2.77-15.55
Volume862,321
Avg Volume2,555,225
Beta0.81
Dividend$0.46
Analyst Ratings
0 Buy 2 Hold 2 Sell
Consensus Hold
Company Info
CEODevdatt Kurdikar
Employees1,850
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2022-03-22
300 Kimball Drive
Parsippany, NJ 07054
US
201 847 6880
About Embecta Corp.

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Recent Insider Trades

NameTypeSharesPriceDate
Roth Anthony M. A-Award 30,000 2026-06-01
Anderson Carrie L A-Award 22,841 2026-02-11
HOMBACH ROBERT J. A-Award 22,841 2026-02-11
Morris Milton Mayo A-Award 22,841 2026-02-11
Prange Karen A-Award 22,841 2026-02-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms